<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678521</url>
  </required_header>
  <id_info>
    <org_study_id>MZentiPTX3</org_study_id>
    <nct_id>NCT01678521</nct_id>
  </id_info>
  <brief_title>Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients</brief_title>
  <official_title>Effect of LDL-apheresis on Pentraxin3 Plasma Levels in Hypercholesterolemic Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional
      pattern-recognition protein, is expressed in many tissues/cells, including innate immunity
      cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert
      protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and
      future cardiovascular risk.

      LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of
      coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the
      procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis
      on plasma PTX3 levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypercholesterolemic patients  with documented CAD, on chronic fortnightly  LDL-apheresis
      treatment will be enrolled in this study.

      Blood samples will be collected before and after a single LDL-Apheresis treatment to asses
      PTX3, HsCRP, IL6, IL10, Fibrinogen and  lipid plasma levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>acute change in PTX3 plasma values</measure>
    <time_frame>before and at the end of one LDL-apheresis treatment (about 6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood samples will be collected before and after a single LDL-apheresis treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute change in hsCRP</measure>
    <time_frame>before and at the end of one LDL-apheresis treatment (about 6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood samples will be collected before and after a single LDL-apheresis treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute change in IL6 and IL10</measure>
    <time_frame>before and at the end of one LDL-apheresis treatment (about 6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood samples will be collected before and after a single LDL-apheresis treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Hypercholesterolemic patients</arm_group_label>
    <description>Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LDL-apheresis</intervention_name>
    <description>The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.</description>
    <arm_group_label>Hypercholesterolemic patients</arm_group_label>
    <other_name>HELP-apheresis</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hypercholesterolemic patients  with documented CAD, on cronic fortnightly  HELP-apheresis
        treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypercholesterolemia

          -  documented CAD

          -  chronic   LDL-apheresis treatment

        Exclusion Criteria:

          -  mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enzo Bonora, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Grazia Zenti, MD</last_name>
    <phone>+390458123110</phone>
    <email>mariagrazia.zenti@univr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riccardo C Bonadonna, MD, PHD</last_name>
    <phone>+390458123115</phone>
    <email>riccardo.bonadonna@univr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endocrinologia e Malattie Metaboliche, Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <state>piazzale Stefani1</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Zenti, MD</last_name>
      <phone>+390458123110</phone>
      <email>mariagrazia.zenti@univr.it</email>
    </contact>
    <contact_backup>
      <last_name>Riccardo C Bonadonna, MD,PHD</last_name>
      <phone>+390458123115</phone>
      <email>riccardo.bonadonna@univr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Grazia Zenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 7, 2012</lastchanged_date>
  <firstreceived_date>August 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Maria Grazia Zenti</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>LDL-apheresis</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>PTX3</keyword>
  <keyword>CRP</keyword>
  <keyword>IL6</keyword>
  <keyword>IL10</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
